Already Raised $24M for our dry powder peptide manufacturing platform to kill cancer cells. Capital came from institutional funds, accredited investors and family offices with 10 issued patents in US, EU, Canada and Australia, 24 more patents pending
First breast cancer collaboration agreement ever signed and funded in Saudi Arabia on 5/11/23
Qualified for $20M in non-dilutive cancer research grants.
10 published scientific articles validating platform
CEO had prior IPO, 72 patents and 11,000+ medical citations. Working with PI from Cleveland Clinic
225 accredited investors in the company
Raising $5M based on clinical pathways in USA and Saudi Arabia with funds and accredited investors and grant awards.
Educational Webinar is available for accredited investors only. We are not selling any securities.